|
1
|
Soerjomataram I, Louwman MW, Ribot JG,
Roukema JA and Coebergh JW: An overview of prognostic factors for
long-term survivors of breast cancer. Breast Cancer Res Treat.
107:309–330. 2008. View Article : Google Scholar :
|
|
2
|
Wang H, Huang M, Zhang DY and Zhang F:
Global profiling of signaling networks: Study of breast cancer stem
cells and potential regulation. Oncologist. 16:966–979. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang H, Zhang F, Ye F, Ma Y and Zhang DY:
The effect of Coptis chinensis on the signaling network in the
squamous carcinoma cells. Front Biosci (Elite Ed). 3:326–340. 2011.
View Article : Google Scholar
|
|
4
|
Zhang F, Song C, Ma Y, Tang L, Xu Y and
Wang H: Effect of fibroblasts on breast cancer cell mammosphere
formation and regulation of stem cell-related gene expression. Int
J Mol Med. 28:365–371. 2011.PubMed/NCBI
|
|
5
|
Xu YC, Wang HX, Tang L, Ma Y and Zhang FC:
A systematic review of vinorelbine for the treatment of breast
cancer. Breast J. 19:180–188. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim R, Tan A, Lai KK, Jiang J, Wang Y,
Rybicki LA and Liu X: Prognostic roles of human equilibrative
transporter 1 (hENT-1) and ribonucleoside reductase subunit M1
(RRM1) in resected pancreatic cancer. Cancer. 117:3126–3134. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jordheim LP, Sève P, Trédan O and Dumontet
C: The ribo-nucleotide reductase large subunit (RRM1) as a
predictive factor in patients with cancer. Lancet Oncol.
12:693–702. 2011. View Article : Google Scholar
|
|
8
|
Metro G, Zheng Z, Fabi A, Schell M,
Antoniani B, Mottolese M, Monteiro AN, Vici P, Lara Rivera S,
Boulware D, et al: In situ protein expression of RRM1, ERCC1, and
BRCA1 in metastatic breast cancer patients treated with
gemcitabine-based chemotherapy. Cancer Invest. 28:172–180. 2010.
View Article : Google Scholar
|
|
9
|
Ishida M, Kushima R and Okabe H: Aberrant
expression of class III beta-tubulin in basal cell carcinoma of the
skin. Oncol Rep. 22:733–737. 2009.PubMed/NCBI
|
|
10
|
Lee MK, Rebhun LI and Frankfurter A:
Posttranslational modification of class III beta-tubulin. Proc Natl
Acad Sci USA. 87:7195–7199. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aquino JB, Musolino PL, Coronel MF, Villar
MJ and Setton-Avruj CP: Nerve degeneration is prevented by a single
intraneural apotransferrin injection into colchicine-injured
sciatic nerves in the rat. Brain Res. 1117:80–91. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dumontet C, Isaac S, Souquet PJ,
Bejui-Thivolet F, Pacheco Y, Peloux N, Frankfurter A, Luduena R and
Perol M: Expression of class III beta tubulin in non-small cell
lung cancer is correlated with resistance to taxane chemotherapy.
Bull Cancer. 92:E25–E30. 2005.PubMed/NCBI
|
|
13
|
Ju BG, Lunyak VV, Perissi V,
Garcia-Bassets I, Rose DW, Glass CK and Rosenfeld MG: A
topoisomerase IIbeta-mediated dsDNA break required for regulated
transcription. Science. 312:1798–1802. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Czajka-Oraniec I and Simpson ER: Aromatase
research and its clinical significance. Endokrynol Pol. 61:126–134.
2010.PubMed/NCBI
|
|
16
|
Sestak I, Kealy R, Nikoloff M, Fontecha M,
Forbes JF, Howell A and Cuzick J: Relationships between CYP2D6
phenotype, breast cancer and hot flushes in women at high risk of
breast cancer receiving prophylactic tamoxifen: Results from the
IBIS-I trial. Br J Cancer. 107:230–233. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shibahara Y, Miki Y, Onodera Y, Hata S,
Chan MS, Yiu CC, Loo TY, Nakamura Y, Akahira J, Ishida T, et al:
Aromatase inhibitor treatment of breast cancer cells increases the
expression of let-7f, a microRNA targeting CYP19A1. J Pathol.
227:357–366. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fritzsche FR, Wassermann K, Jung M, Tölle
A, Kristiansen I, Lein M, Johannsen M, Dietel M, Jung K and
Kristiansen G: ADAM9 is highly expressed in renal cell cancer and
is associated with tumour progression. BMC Cancer. 8:1792008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Györffy B, Lanczky A, Eklund AC, Denkert
C, Budczies J, Li Q and Szallasi Z: An online survival analysis
tool to rapidly assess the effect of 22,277 genes on breast cancer
prognosis using microarray data of 1,809 patients. Breast Cancer
Res Treat. 3:725–731. 2010. View Article : Google Scholar
|
|
20
|
Simon R: Roadmap for developing and
validating therapeutically relevant genomic classifiers. J Clin
Oncol. 23:7332–7341. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Glas AM, Floore A, Delahaye LJ, Witteveen
AT, Pover RC, Bakx N, Lahti-Domenici JS, Bruinsma TJ, Warmoes MO,
Bernards R, et al: Converting a breast cancer microarray signature
into a high-throughput diagnostic test. BMC Genomics. 7:2782006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rha SY, Jeung HC, Choi YH, Yang WI, Yoo
JH, Kim BS, Roh JK and Chung HC: An association between RRM1
haplotype and gemcitabine-induced neutropenia in breast cancer
patients. Oncologist. 12:622–630. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vici P, Fabi A, Metro G, Sergi D,
Giannarelli D, Di Lauro L, Bepler G, Tomao F, Cognetti F, Conti F,
et al: Phase I–II trial of prolonged gemcitabine infusion plus
paclitaxel as a biweekly schedule for advanced breast cancer
patients pretreated with anthracyclines. Cancer Chemother
Pharmacol. 67:687–693. 2011. View Article : Google Scholar
|
|
24
|
Davidson JD, Ma L, Flagella M, Geeganage
S, Gelbert LM and Slapak CA: An increase in the expression of
ribonucleotide reductase large subunit 1 is associated with
gemcitabine resistance in non-small cell lung cancer cell lines.
Cancer Res. 64:3761–3766. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yen Y: Ribonucleotide reductase subunit
one as gene therapy target: commentary re: M–Y. Cao et al:
Adenovirus-mediated ribonucleotide reductase R1 gene therapy of
human colon adenocarcinoma. Clin Cancer Res. 9:4304–4308.
2003.PubMed/NCBI
|
|
26
|
Rosell R, Felip E, Taron M, Majo J, Mendez
P, Sanchez-Ronco M, Queralt C, Sanchez JJ and Maestre J: Gene
expression as a predictive marker of outcome in stage IIB-IIIA-IIIB
non-small cell lung cancer after induction gemcitabine-based
chemotherapy followed by resectional surgery. Clin Cancer Res.
10:4215s–4219s. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim D, Jung W and Koo JS: The expression
of ERCC1, RRM1, and BRCA1 in breast cancer according to the
immunohistochemical phenotypes. J Korean Med Sci. 26:352–359. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang LR, Zhang GB, Chen J, Li J, Li MW, Xu
N, Wang Y and Shen Tu JZ: RRM1 gene expression in peripheral blood
is predictive of shorter survival in Chinese patients with advanced
non-small-cell lung cancer treated by gemcitabine and platinum. J
Zhejiang Univ Sci B. 12:174–179. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pesta M, Kulda V, Fiala O, Safranek J,
Topolcan O, Krakorova G, Cerny R and Pesek M: Prognostic
significance of ERCC1, RRM1 and BRCA1 in surgically-treated
patients with non-small cell lung cancer. Anticancer Res.
32:5003–5010. 2012.PubMed/NCBI
|
|
30
|
Azuma K, Sasada T, Kawahara A, Takamori S,
Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, et al:
Expression of ERCC1 and class III beta-tubulin in non-small cell
lung cancer patients treated with carboplatin and paclitaxel. Lung
Cancer. 64:326–333. 2009. View Article : Google Scholar
|
|
31
|
Burkhart CA, Kavallaris M and Band Horwitz
S: The role of beta-tubulin isotypes in resistance to antimitotic
drugs. Biochim Biophys Acta. 1471:O1–O9. 2001.PubMed/NCBI
|
|
32
|
Cheng MH, Yang YC, Wong YH, Chen TR, Lee
CY, Yang CC, Chen SH, Yang IN, Yang YS, Huang HS, et al: B1, a
novel topoisomerase II inhibitor, induces apoptosis and cell cycle
G1 arrest in lung adenocarcinoma A549 cells. Anticancer Drugs.
23:191–199. 2012. View Article : Google Scholar
|
|
33
|
Chen S, Fariss RN, Kutty RK, Nelson R and
Wiggert B: Fenretinide-induced neuronal differentiation of ARPE-19
human retinal pigment epithelial cells is associated with the
differential expression of Hsp70, 14-3-3, pax-6, tubulin beta-III,
NSE, and bag-1 proteins. Mol Vis. 12:1355–1363. 2006.PubMed/NCBI
|
|
34
|
Carrara L, Guzzo F, Roque DM, Bellone S,
Emiliano C, Sartori E, Pecorelli S, Schwartz PE, Rutherford TJ and
Santin AD: Differential in vitro sensitivity to patupilone versus
paclitaxel in uterine and ovarian carcinosarcoma cell lines is
linked to tubulin-beta-III expression. Gynecol Oncol. 125:231–236.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Uppala PT, Dissmore T, Lau BH, Andacht T
and Rajaram S: Selective inhibition of cell proliferation by
lycopene in MCF-7 breast cancer cells in vitro: A proteomic
analysis. Phytother Res. 27:595–601. 2013. View Article : Google Scholar
|
|
36
|
Zhao HY, Huang H, Hu ZH, Huang Y, Lin SX,
Tian Y and Lin TY: Evaluations of biomarkers associated with
sensitivity to 5-fluorouracil and taxanes for recurrent/advanced
breast cancer patients treated with capecitabine-based first-line
chemotherapy. Anticancer Drugs. 23:534–542. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hellemans P, van Dam PA, Geyskens M, van
Oosterom AT, Buytaert P and Van Marck E: Immunohistochemical study
of topoisomerase II-alpha expression in primary ductal carcinoma of
the breast. J Clin Pathol. 48:147–150. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fountzilas G, Christodoulou C, Bobos M,
Kotoula V, Eleftheraki AG, Xanthakis I, Batistatou A,
Pentheroudakis G, Xiros N, Papaspirou I, et al: Topoisomerase II
alpha gene amplification is a favorable prognostic factor in
patients with HER2-positive metastatic breast cancer treated with
trastuzumab. J Transl Med. 10:2122012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hadfield KD and Newman WG:
Pharmacogenetics of aromatase inhibitors. Pharmacogenomics.
13:699–707. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Damodaran SE, Pradhan SC, Umamaheswaran G,
Kadambari D, Reddy KS and Adithan C: Genetic polymorphisms of
CYP2D6 increase the risk for recurrence of breast cancer in
patients receiving tamoxifen as an adjuvant therapy. Cancer
Chemother Pharmacol. 70:75–81. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Vilmar A, Garcia-Foncillas J, Huarriz M,
Santoni-Rugiu E and Sorensen JB: RT-PCR versus immunohistochemistry
for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1
in NSCLC. Lung Cancer. 75:306–312. 2012. View Article : Google Scholar
|
